Results 11 to 20 of about 882 (153)

Potency of Meropenem-Vaborbactam in Lung Surfactant [PDF]

Antimicrobial Agents and Chemotherapy, 2018
This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several
Debora Rubio-Aparicio, Michael Dudley, Olga Lomovskaya, Jeff Loutit   +3 more
core   +3 more sources

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

Journal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and ...
Hung-Jen Tang, Chi-Chung Chen, Chih-Cheng Lai   +2 more
core   +4 more sources

Profiling interactions of vaborbactam with metallo-β-lactamases [PDF]

Bioorganic & Medicinal Chemistry Letters, 2019
β-Lactams are the most successful antibacterials, yet their use is threatened by resistance, importantly as caused by β-lactamases. β-Lactamases fall into two mechanistic groups: the serine β-lactamases that utilise a covalent acyl-enzyme mechanism and ...
Cain, Ricky, Calvopiña, K, Widlake, E, Langley, Gareth W., Langley, GW, Hinchliffe, Philip, Walsh, TR, Brem, Jürgen, Tooke, CL, Hinchliffe, P, Tyrrell, Jonathan M., Walsh, Timothy R., Tooke, Catherine L., Cain, R, Spencer, J, Brem, J, Widlake, Emma, Calvopiña, Karina, Dowson, Christopher G., Dowson, CG, Tyrrell, JM, Spencer, James, Schofield, Christopher J., Schofield, CJ, Schofield, Christopher   +24 more
core   +12 more sources

In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin

Future Microbiology, 2023
International audienceAim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. ( Achr), Burkholderia cepacia complex ( Bcc) and Stenotrophomonas maltophilia ( Smal).
Moussalih, Sophie, Alauzet, Corentine, Crémet, Lise, Guillard, Thomas, de Verdière, Sylvie, Farfour, Eric, D’epenoux, Louise Ruffier, Corvec, Stéphane, Vasse, Marc, Muggeo, Anaëlle, Bosphore, Amélie, Roux, Antoine   +11 more
core   +8 more sources

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae

Infection and Drug Resistance, 2018
Lindsay A Petty,1 Oryan Henig,1 Twisha S Patel,2 Jason M Pogue,3 Keith S Kaye1 1Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Pharmacy Services, University of ...
Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS   +4 more
doaj   +1 more source

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam [PDF]

Infectious Diseases and Therapy, 2020
Plain Language Summary Carbapenem-resistant gram-negative pathogens, specifically, Enterobacteriaceae, remain an urgent public health threat, and safe, effective treatment options are limited. The antibiotic agents meropenem and vaborbactam were selected
Eric Wenzler, Patrick J. Scoble
doaj   +3 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Antibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin, Sandrine Bernabeu, Cécile Emeraud, Thierry Naas, Delphine Girlich, Agnès B. Jousset, Laurent Dortet   +6 more
doaj   +2 more sources

Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales [PDF]

Journal of Antimicrobial Chemotherapy, 2023
The treatment options for infections caused by carbapenem-resistant Enterobacterales (CRE) are extremely scarce nowadays and the development of new antibiotics does not follow the exponential increase in the dissemination of carbapenem resistance ...
Maxime Bouvier, Laurent Poirel, Sadek, M., Otávio Hallal Ferreira Raro, Nordmann, P., Kerbol, A., Poirel, L., Raro, OHF, Mustafa Sadek, Patrice Nordmann, Auriane Kerbol, Bouvier, M.   +11 more
core   +4 more sources

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa

Antibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group   +24 more
doaj   +2 more sources

Pharmacokinetics, safety and population pharmacokinetics/pharmacodynamics analysis of meropenem-vaborbactam in Chinese healthy participants

Frontiers in Pharmacology
BackgroundMeropenem-vaborbactam is a fixed-dose β-lactam/β-lactamase inhibitor combination active against carbapenem-resistant Enterobacterales (CRE), especially Klebsiella pneumoniae carbapenemase (KPC)-producing CRE.
Wanzhen Li, Wanzhen Li, Qiong Wei, Mengting Chen, Mengting Chen, Xiaofen Liu, Xiaofen Liu, Beining Guo, Beining Guo, Yuancheng Chen, Qi Zhang, Wei Guan, Long Shen, Xiaohui Wang, Nanyang Li, Yan Chen, Yan Chen, Xin Li, Xin Li, Yingying Hu, Jing Zhang, Jing Zhang, Jing Zhang, Xiaojie Wu, Xiaojie Wu   +24 more
doaj   +2 more sources